ArticleCritical care (London, England)2009
Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?
Article in Critical care (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Vasopressin in cardiogenic shock: pathophysiology, clinical evidence, and therapeutic perspectives.ESC heart failure · 2026Article
- Management of cardiogenic shock: state-of-the-art.Intensive care medicine · 2024Review
- Serum Copeptin in Cardiooncology Practice: Review of Pathophysiological and Clinical Implications.Balkan medical journal · 2023Article
- Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass.The Eurasian journal of medicine · 2022Article
- Safety of renal biopsy bleeding prophylaxis with desmopressin.The Journal of international medical research · 2021Article
- Plasma Histone H4 and Its Implications in the Setting of Sepsis-related Myocardial DysfunctionBalkan medical journal · 2020Article
- Year in review 2009: Critical Care--shock.Critical care (London, England) · 2010Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During advanced vasodilatory shock, arginine vasopressin (AVP) is increasingly used to restore blood pressure and thus to reduce catecholamine requirements. The AVP-related rise in mean arterial pressure is due to systemic vasoconstriction, which, depending on the infusion rate, may also reduce coronary blood flow despite an increased coronary perfusion pressure. In a murine model of myocardial ischaemia, Indrambarya and colleagues now report that a 3-day infusion of AVP decreased the left ventricular ejection fraction, ultimately resulting in increased mortality, and thus compared unfavourably with a standard treatment using dobutamine. The AVP-related impairment myocardial dysfunction did not result from the increased left ventricular afterload but from a direct effect on cardiac contractility. Consequently, the authors conclude that the use of AVP should be cautioned in patients with underlying cardiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.